Login to Your Account

Week in Review

Monday, November 7, 2011


Clovis Oncology Inc. set terms for its proposed $130.2 million initial public offering.

Dynavax Technologies Corp. raised $60 million in a public stock offering.

Human Genome Sciences Inc. priced a public offering of $494.5 million in convertible senior notes.

Karyopharm Therapeutics Inc. completed a $10 million Series A2 financing.

Verastem Inc. filed to raise $50 million in an initial public offering.


To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription